Study of association between molecular marker expression on tumor and immunocompetent cells and sensitivity to adjuvant and neoadjuvant therapy of bladder cancer

Use of immunotherapy in treatment of muscle-invasive bladder cancer remains the most promising method in case of impossibility of chemotherapy with cisplatin or progression during cisplatin treatment. This approach is the method of choice and can prolong patient’s life. In particular, use of checkpoint inhibitors allows to obtain effective treatment of bladder cancer. However, to prescribe immunotherapeutic medication, patient must have point of application for these drugs. Individualized approach will allow to increase treatment effectiveness and disease prognosis while maximally improving the quality of life.

1. State of oncological care in Russia in 2017. Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS radiologii” Minzdrava Rossii, 2018. 236 p. (In Russ.).

2. Said N. Roles of SPARC in urothelial carcinogenesis, progression and metastasis. Oncotarget 2016;7(41):67574–85. DOI: 10.18632/oncotarget.11590.

3. Volkova M.I., Matveev V.B., Medvedev S.V. et al. Clinical guidelines of diagnosis and treatment of patients with bladder cancer. Moscow, 2014. (In Russ.).

4. Clinical oncourology. Ed. B.P. Matveev. Moscow, 2011. (In Russ.).

5. Choudhury N.J., Kiyotani K., Yap K.L. et al. Low T-cell receptor diversity, high somatic mutation burden, and high neoantigen load as predictors of clinical outcome in muscle-invasive bladder cancer. Eur Urol Focus 2016;2(4): 445–52. DOI: 10.1016/j.euf.2015.09.007.

6. Karyakin O.B. Bladder cancer: What’s new in 2017– 2018? XIII Congress of Russian Association of Oncourology October 04–05, 2018. (In Russ.).

7. Choi W., Porten S., Kim S. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014;25(2):152– 65. DOI: 10.1016/j.ccr.2014.01.009.

8. Safiullin K.N. Treatment of non-muscleinvasive bladder cancer: Thesis … of doctor of medical sciences. Obninsk, 2012. (In Russ.).

9. Bladder cancer (classics and innovations). Chapter 8. Ed. M.I. Kogan. Moscow: Medforum, 2017. 262 p. (In Russ.).

10. Ivanov S.A., Zaborskiy I.N., Chaykov V.S. Treatment of non-muscle-invasive highrisk bladder cancer. Vestnik urologii = Urology Herald 2017;5(2):42–9. (In Russ.) DOI: 10.21886/2308-6424-2017-5-2-42-49.

11. Hautmann R.E., de Petriconi R.C., Pfeiffer C., Volkmer B.G. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 2012;61(5):1039–47. DOI: 10.1016/j.eururo.2012.02.028.

12. Bladder cancer (classics and innovations). Chapter 9. Ed. M.I. Kogan. Moscow: Medforum, 2017. 262 p. (In Russ.).

13. European Association of Urology (EAU). Guidelines.

14. Kluchagina Yu.I., Sokolova Z.A., Baryshnikova M.A. Role of PD-1 receptor and its ligands PD-L1 and PD-L2 in cancer immunotherapy. Onkopediatriya = Oncopediatrics 2017;4(1):49–55. (In Russ.).

15. Reutova E.V., Laktionov K.P., Breder V.V. et al. Immunemediated adverse eventa associated with immune checkpoint inhibitors therapy. Zlokachestvennye opukholi = Malignant Tumors 2016;4(20):68–76. (In Russ.) DOI: 10.18027/22245057-2016-4-68-76.

16. Volkova M.I., Gridneva Ya.V., Ol’shanskaya A.S. Immunotherapy in urothelial cancer: recent data and perspectives. Onkourologiya = Cancer Urology 2017;13(4):16–24. (In Russ.).

17. Kadagidze Z.G., Chertakova A.I. Immune system and cancer. Prakticheskaya onkologiya = Practical Oncology 2016;17(2):62–73. (In Russ.).

18. Borisov K.E., Sakaeva D.D. Tumor microenvironment as a target of malignant gliomas treatment. Zlokachestvennye opukholi = Malignant Tumors 2015;(4):14–23. (In Russ.).

19. Perelmuter V.M., Tashireva L.A., Manskikh V.N. et al. Heterogeneity and plasticity of immune-inflammatory responses in tumor microenvironment: a role in antitumor effect and tumor aggressiveness. Zhurnal obshchey biologii = Journal of General Biology 2017;78(5):15–36. (In Russ.).

20. Shubina I.Zh., Sergeev A.V., Mamedova L.T. et al. Current understanding of antitumor immunity. Rossiyskiy bioterapevticheskiy zhurnal = Russian Biotherapeutic Journal 2015;14(3):19–28. (In Russ.). DOI: 10.17650/1726-9784-2015-14-3-19-28.

21. Svensson M.C., Warfvinge C.F., Fristedt R. et al. The integrative clinical impact of tumorinfiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma. Oncotarget 2017;8(42):72108–26. DOI: 10.18632/oncotarget.19437.

22. Donadon M., Hudspeth K., Cimino M. et al. Increased infiltration of natural killer and T cells in colorectal liver metastases improves patient overall survival. J Gastrointestinal Surg 2017;21(8):1226–36. DOI: 10.1007/s11605-017-3446-6.

23. Gu-Trantien C., Loi S., Garaud S. et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J Clin Investigat 2018;123(7):2873–92. DOI: 10.1172/JCI67428.

24. Yang L., Pang Y., Moses H.L. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010;31(6):220–7. DOI: 10.1016/j.it.2010.04.002.

25. Keskinova A.A., Shchurin M.R., Bukhman V.M., Shprakh Z.S. Impact of tumor-derived factors on dendritic cells in cancer. Rossiyskiy bioterapevticheskiy zhurnal = Russian Biotherapeutic Journal 2017;16(1):12–23. (In Russ.). DOI: 10.17650/1726-9784-2017-16-1-1223

26. Ha T.Y. The role of regulatory T cells in cancer. Immune Netw 2009;9(6):209–35. DOI: 10.4110/in.2009.9.6.209.

27. Albeituni S.H., Ding Ch., Yan J. Hampering the immune suppressors: therapeutic targeting of myeloid-derived suppressor cells (MDSC) in cancer. Cancer 2013;19(6):490–501. DOI: 10.1097/PPO.0000000000000006.

28. Cherdyntseva N.V., Mitrofanova I.V., Buldakov M.A. et al. Macrophages and tumor progression: on the way to macrophagespecific therapy. Bulleten’ sibirskoy meditsyny = Bulletin of Siberian Medicine 2017;16(4):61–74. (In Russ.). DOI: 10.20538/1682-0363-2017-4-61-74.

29. Klyuchagina Yu.I., Sokolova Z.A., Baryshnikova M.A. Role of PD-1 receptor and its ligands PD-L1 and PD-L2 in cancer immunotherapy. Onkopediatriya = Oncopediatrics 2017;4(1):49–55. (In Russ.). DOI: 10.15690/onco.v4i1.1684.

30. Zhulay G.A., Oleynik E.K. CD4+CD25+FOXP3+ regulatory T-lymphocyte. Prospective applications in immunotherapy. Trudy Karel’skogo nauchnogo tsentra RAN = Transactions of Karelian Research Center of Russian Academy of Science 2012;2:3–17. (In Russ.).

31. Sayapina M.S. Immunoregulatory functions of PD-1/PD-L1 inhibitors and development of resistance to them. Zlokachestvennye opukholi = Malignant Tumors 2017;7(2):94–9. (In Russ.).

32. Zhao B., Zhang W., Yu D. et al. The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials. Cancer Med 2018;7(5): 1642–59. DOI: 10.1002/cam4.1387.

33. Hu H., Zhu Q., Shi X. et al. Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis. Oncotarget 2018;9(14):11846–57. DOI: 10.18632/oncotarget.24163.

34. Mikhaylenko D.S., Sergienko S.A., Zaborsky I.N. et al. The role of molecular genetic alterations in sensitivity of the adjuvant intravesical therapy for non-muscle invasive bladder cancer. Onkourologiya = Cancer Urology 2018;14(4):124–38. (In Russ.). DOI: 10.17650/1726-9776-2018-14-4124-138.

35. Blaylock R.L. Cancer microenvironment, inflammation and cancer stem cells: a hypothesis for a paradigm change and new targets in cancer control. Surg Neurol Int 2015;6:92. DOI: 10.4103/21527806.157890.

36. Wu A.A., Drake V., Huang H.S. et al. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology 2015;4:e1016700. DOI: 10.1080/2162402X.2015.1016700.

37. Easwaran H., Tsai H.C., Baylin S.B. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 2014;54:716–27. DOI: 10.1016/j.molcel.2014.05.015.

38. Kaprin A.D., Galkin V.N., Zhavoronkov L.P. et al. Synthesis of basic and applied research is the basis of obtaining high-quality findings and translating them into clinical practice. Radiation Risk 2017;26(2):26–40. DOI: 10/21870/0131-3878-2017-26-2-26-40.